Back to search

University of Southampton

Development and clinical applications of improved assays for detection and quantitation of hepatitis C virus

Abstract

dc:description.abstract

<p>For this project, a real-time PCR-based assay was developed for detection and quantitation of HCV RNA using the TaqMan 5' nuclease assay and the Applied Biosystems PRISM 7700 Sequence Detection System.</p><p>TaqMan primers and probes were designed to amplify part of the 5' untranslated region and detected HCV genotypes 1 - 5 with equal efficiency. An HCV standard RNA was developed and used to generate standard curves for quantitation. An internal control RNA was produced and used to monitor efficiency of RNA extraction reverse transcription and amplification. </p><p>The performance of the assay was evaluated using the World Health Organisation International Standard for HCV RNA. The assay quantified the International Standard to within a mean of 27% from the published load and had a limit of detection of 50 international units/ml. The assay had a wide dynamic range (50 - 10<sup>8</sup> copies/ml) and had intra and inter-assay coefficients of variation of 23.8% and 29.4%, respectively. The assay was compared with the Quantiplex HCV RNA 2.0 assay (Bayer) and viral loads given by the two assays correlated strongly.</p><p>The quantitative assay was used to study HCV load in 53 symptomatic and 57 asymptomatic chronically infected individuals. No difference in load was found between the two populations. When the groups were combined, a weak correlation was found between viral load and the level of liver fibrosis. Longitudinal variation in load was also studied in 19 asymptomatic patients. Of these, eight showed an increase in load, ten showed a decrease and one showed no overall change in load. Viral load varied by <11og<sub>10</sub> copies/ml in the majority of patients (68%).</p><p>HCV loads were also studied in eight HCV-positive patients treated with a combination of pegylated interferon and ribavirin (Roche). End of treatment virological and biochemical responses rates were 87.5% and 78%, respectively and the overall end of treatment response rate was 75%. Highest rates of decline in viral load were seen in patients infected with genotype 3 virus.</p><p>The assay was also used to quantify HCV RNA in cultured peripheral blood mononuclear cells from HCV-positive patients. The cells were treated with immunomodulatory compounds (cyclosporin A, hydrocortisone, phytohaemagglutinin) and HCV RNA levels measured. HCV RNA levels decreased in all treated and untreated cells over the study period (seven to 14 days). The addition of the immunomodulatory compounds had no detectable effects on virus levels.</p>

Degree

thesis:*
Name dc:type.qualificationname
Ph.D.
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Southampton
Year dc:date.issued
2002

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Hadfield, Stephen J

Rights

Language dc:language
English, eng

Chain of custody

source
Harvested from
University of Southampton
Base URL
eprints.soton.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Hadfield, Stephen J. Development and clinical applications of improved assays for detection and quantitation of hepatitis C virus. doctoral thesis, University of Southampton, 2002.